Shots:
- AstraZeneca to acquire EsoBiotec, which will operate as AstraZeneca’s subsidiary, while maintaining its operations in Belgium to advance cell therapy
- As per the deal, AstraZeneca will acquire all outstanding equity of EsoBiotec on a cash & debt-free basis for ~$1B, incl. $425M upfront at closing & ~$575M in development & regulatory milestones; closing is expected Q2’25
- Acquisition will add EsoBiotec’s ENaBL platform, enhancing AstraZeneca’s cell therapy capabilities by utilizing targeted lentiviruses which can be administered via IV to deliver genetic instructions to immune cells, programming them to destroy tumor cells without immune cell depletion
Ref: AstraZeneca | Image: EsoBiotec
Related News:- AstraZeneca Reports the EC’s Approval of Imfinzi to Treat Limited-Stage Small Cell Lung Cancer (LS-SCLC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
